| Chemical Name |
CHPG |
| CAS Number |
170846-74-9 |
| MDL Number |
MFCD01321059 |
| Molecular Formula |
C8H8ClNO3 |
| Molecular Weight |
201.61 |
Introduction of 170846-74-9 :
CHPG is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells[1]. CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways[2]. IC50 & Target: mGluR5, TSG-6/NF-κB[1], ERK, Akt[2] In Vitro: CHPG (10-500 µM; 24 hours) significantly increases the cell viability and decreases the LDH release after SO2 derivatives treatment[1].
CHPG (0.5 mM; 30 mins ) protects BV2 cells against SO2-induced apoptosis[1].
CHPG (0.5 mM; 30 mins) treatment alone increases the expression of TSG-6 in both mRNA and protein levels[1].
In Vivo: CHPG (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume[2].
| Purity |
NLT 98% |
| Storage |
at 20ºC 2 years |
*The above information is for reference only.
